Articles: function.
-
OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The most suitable treatment for OSAS is the CPAP. However there are patients who don't tolerate it. A therapeutic not surgical alternative is MAD . It consists of a plastic rod which being introduced in dental arcades produces the advance of the jaw and indirectly the advance of the tongue, hyoid and suprahyoidea musculature. All this implies a space and permeability increase of the top airway. Our objective is to evaluate the efficiency of the MAD, Herbst type, as a treatment for OSAS. This evaluation will be carried out by means of clinic and functional variables. ⋯ The following authors have nothing to disclose: Maria Pavón, Estefania Luque, Jose María Benitez, Jesús Sánchez, Andrés Vega Arias, Teodoro MontemayorNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The IGNITE program investigated the efficacy and safety of dual bronchodilation with once-daily QVA149 [fixed-dose combination of indacaterol (long-acting β2-agonist) and glycopyrronium (long-acting muscarinic antagonist)] for the treatment of patients with moderate-to-severe COPD. ⋯ Karen Mezzi: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Critical care medicine · Mar 2014
FTY720 (S)-Phosphonate Preserves Sphingosine 1-Phosphate Receptor 1 Expression and Exhibits Superior Barrier Protection to FTY720 in Acute Lung Injury.
Effective therapies are needed to reverse the increased vascular permeability that characterizes acute inflammatory diseases such as acute lung injury. FTY720 is a pharmaceutical analog of the potent barrier-enhancing phospholipid, sphingosine 1-phosphate. Because both FTY720 and sphingosine 1-phosphate have properties that may limit their usefulness in patients with acute lung injury, alternative compounds are needed for therapeutic use. The objective of this study is to characterize the effects of FTY720 (S)-phosphonate, a novel analog of FTY720-phosphate, on variables of pulmonary vascular permeability in vitro and alveolar-capillary permeability in vivo. ⋯ FTY720 (S)-phosphonate is a promising barrier-promoting agent that effectively maintains sphingosine 1-phosphate receptor 1 levels and improves outcomes in the bleomycin model of acute lung injury.
-
Pleural Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Patients coming for preoperative evaluation are often diagnosed for first time with underlying diseases that go unnoticed unless patients present for evaluation. One such example is hypoxia. We present 74 year-old male with no significant past medical history coming for preoperative evaluation for cataract surgery and was hypoxic. With careful assessment of history and physical exam along with imaging revealed asbestosis, thus highlighting importance of occupational exposure. ⋯ The following authors have nothing to disclose: Meenal Malviya, Asad Omar, Navneet Kumar, Muhammad EhteshamNo Product/Research Disclosure Information.
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: To assess the effectiveness of inhaled colistin in elderly patients with bronchiectasis and chronic bronchial PA infection in reducing hospital readmissions ⋯ The following authors have nothing to disclose: Eva Tabernero, Pilar Gil, Ramon Alkiza, Javier Garros, Anibal Hernandez, Juan Luis ArtolaNo Product/Research Disclosure Information.